Inactive Instrument

Press Releases TURG POIN

Equities

TPTX

US90041T1088

Press Releases

Unlock all the news: Be the first to know and act before the market!

Turning Point Therapeutics : Statement of Changes in Beneficial Ownership - Form 4	22-08-17	PU
Turning Point Therapeutics : Statement of Changes in Beneficial Ownership - Form 4	22-08-17	PU
Turning Point Therapeutics : Statement of Changes in Beneficial Ownership - Form 4	22-08-17	PU
Turning Point Therapeutics : Statement of Changes in Beneficial Ownership - Form 4	22-08-17	PU
Turning Point Therapeutics : Statement of Changes in Beneficial Ownership - Form 4	22-08-17	PU
Turning Point Therapeutics : Statement of Changes in Beneficial Ownership - Form 4	22-08-17	PU
Turning Point Therapeutics : Statement of Changes in Beneficial Ownership - Form 4	22-08-17	PU
Turning Point Therapeutics : Statement of Changes in Beneficial Ownership - Form 4	22-08-17	PU
Turning Point Therapeutics : Statement of Changes in Beneficial Ownership - Form 4	22-08-17	PU
Turning Point Therapeutics : Statement of Changes in Beneficial Ownership - Form 4	22-08-17	PU
Turning Point Therapeutics : Statement of Changes in Beneficial Ownership - Form 4	22-08-17	PU
Turning Point Therapeutics : Termination of a Material Definitive Agreement - Form 8-K	22-08-17	PU
TURNING POINT THERAPEUTICS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	22-08-17	AQ
Turning Point Therapeutics : Positive feedback from pre-new drug application (NDA) meeting with U.S. Food and Drug Administration (FDA) focused on TRIDENT-1 registrational study of repotrectinib Initiated the Phase 1b/2 SHIELD-2 combination study of elzovantinib and aumolertinib in EGFR mutant MET-amplified advanced non-small cell lung cancer (NSCLC) Plan to provide detailed update for TRIDENT-1 registrational ROS1-positive NSCLC population and additional data for NTRK-positive solid tumor population, as we	22-08-08	PU
Turning Point Therapeutics: Q2 Earnings Snapshot	22-08-08	AQ
TURNING POINT THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-08-08	AQ
TURNING POINT THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	22-08-08	AQ
Turning Point Therapeutics Reports Second-Quarter 2022 Financial Results, Provides Operational Updates	22-08-08	AQ
Turning Point Therapeutics : Statement of Changes in Beneficial Ownership - Form 4	22-07-29	PU
Turning Point Therapeutics Provides Regulatory Update for Repotrectinib for the Treatment of ROS1+ Advanced NSCLC	22-07-27	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases TURG POIN

Equities

TPTX

US90041T1088

Press Releases

Filters